Core Viewpoint - Hongyuan Pharmaceutical (301246) expects a significant increase in net profit for the year 2025, projecting a range of approximately 113 million to 137 million yuan, representing a growth of 119.57% to 166.2% compared to the previous year [2] Group 1: Financial Performance - The company anticipates a substantial rise in operating performance for 2025 compared to the same period last year [2] - The expected profit growth is primarily driven by the lithium hexafluorophosphate business [2] Group 2: Market Demand - The demand for new energy vehicles continues to grow, contributing positively to the company's performance [2] - There is a rapid increase in demand within the energy storage market, which has significantly improved the profitability of the lithium hexafluorophosphate business [2]
宏源药业2025年净利预增119.57%至166.2%